A randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab in metastatic colorectal cancer patients with RAS wild-type tumors

ABSTRACT: Primary outcome(s): Deepness of Response(DpR) Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

DISEASE(S): Colorectal Cancer

PROVIDER: 2615586 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR